greeksoup/ stock research
Stock research / United States / AZN / Year to 31 December 2024

AstraZeneca PLC (AZN) annual results, year to 31 December 2024: revenue USD 54,073 million, from the 20-F

AstraZeneca PLC files a 20-F with the SEC once a year, in US dollars. In the year to 31 December 2024 it reported revenue of USD 54,073 million, up 18.0% on the year before. Its profit attributable to shareholders was USD 7,035 million, up 18.1%, and diluted earnings per share USD 4.50.

Revenue
USD 54,073 million
+18.0% on the year
FY2017FY2024
Operating margin
18.5%
17.9% a year earlier
FY2017FY2024
Net income
USD 7,035 million
+18.1% on the year
FY2017FY2024
Diluted EPS
USD 4.50
+18.1% on the year
FY2017FY2024

this yearthe year beforeIn US dollars as filed. Hover a bar for its figure.

Income statement (profit and loss)

Year toDec 2023Dec 2024
Revenue45,81154,073
Cost of sales8,26810,207
Gross profit37,54343,866
Research and development10,93513,583
Selling, general and administrative19,21619,977
Operating profit8,19310,003
Finance costs1,6261,742
Profit before tax6,8998,691
Income tax9381,650
Profit for the year5,9617,041
Profit attributable to shareholders5,9557,035
Filing20-F20-F
USD million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated.
Year toDec 2023Dec 2024
Diluted EPS3.814.50
Basic EPS3.844.54
Filing20-F20-F

USD per ordinary share, as filed.

Cash flow

Year toDec 2023Dec 2024
Cash from operations10,34511,861
Purchase of property, plant and equipment1,3611,924
Free cash flow8,9849,937
Cash from investing-4,064-7,980
Cash from financing-6,567-3,996
Buybacksn/a81.0
Dividends paid4,4814,629
Filing20-F20-F

USD million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.

Balance sheet

Year toDec 2023Dec 2024
Funded by
Equity attributable to shareholders39,14340,786
Non-controlling interests23.085.0
Borrowings, as filed27,49428,843
Lease liabilities1,1281,452
Other liabilities33,33132,869
Total equity and liabilities101,119104,035
Owned
Property, plant and equipment9,40210,252
Goodwill20,04821,025
Other intangible assets38,08937,177
Cash and cash equivalents5,8405,488
Trade and other receivables12,12612,972
Inventories5,4245,288
Other assets10,19011,833
Total assets101,119104,035
Filing20-F20-F

USD million, at each fiscal year end.

Ratios on the filed lines

Year toDec 2023Dec 2024
Gross margin82.0%81.1%
Operating margin17.9%18.5%
Net margin13.0%13.0%
Free cash flow margin19.6%18.4%
Return on year-end equity15.2%17.2%
Effective tax rate13.6%19.0%
Filing20-F20-F

Arithmetic on the filed lines of the same year.

20-F for the year to 31 December 2024, filed 24 February 2026: the filing. The figures are in US dollars as filed.